Ginkgo Bioworks reported Q2 2026 revenue of $20 million, down 48% year over year, reflecting continued pressure as it shifts focus toward autonomous laboratory systems, contract research services, and related software. The sharp decline suggests near-term execution and demand headwinds during the business transition.
Ginkgo Bioworks reported Q2 2026 revenue of $20 million, down 48% year over year, reflecting continued pressure as it shifts focus toward autonomous laboratory systems, contract research services, and related software. The sharp decline suggests near-term execution and demand headwinds during the business transition.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.35
Ticker Sentiment
